Volasertib (BI 6727) (11 in Figure 3), by Boehringer Ingelheim, is a dihydropteridinone-derived, ATP-competitive kinase inhibitor of PLK1, active in preclinical studies on various cancers and is being tested as anticancer agent in many clinical trials [84]. The gene discussed is PLK1; the disease is cancer.